找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cancer Drug Safety and Public Health Policy; A Changing Landscape Charles Bennett,Courtney Lubaczewski,Bartlett With Book 2022 The Editor(s

[复制链接]
查看: 18079|回复: 50
发表于 2025-3-21 16:49:00 | 显示全部楼层 |阅读模式
书目名称Cancer Drug Safety and Public Health Policy
副标题A Changing Landscape
编辑Charles Bennett,Courtney Lubaczewski,Bartlett With
视频video
概述Analyzes current policy trends regarding cancer drug safety.Explains the policy implications of recent legal settlements.Covers issues in identification and reporting of ADRs
丛书名称Cancer Treatment and Research
图书封面Titlebook: Cancer Drug Safety and Public Health Policy; A Changing Landscape Charles Bennett,Courtney Lubaczewski,Bartlett With Book 2022 The Editor(s
描述.This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety
出版日期Book 2022
关键词Health Policy; Novel Informatics; Pharmacovigilance; Cancer Drug Safety; Cancer Blockbuster Drogs; Pharma
版次1
doihttps://doi.org/10.1007/978-3-031-04402-1
isbn_softcover978-3-031-04404-5
isbn_ebook978-3-031-04402-1Series ISSN 0927-3042 Series E-ISSN 2509-8497
issn_series 0927-3042
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

书目名称Cancer Drug Safety and Public Health Policy影响因子(影响力)




书目名称Cancer Drug Safety and Public Health Policy影响因子(影响力)学科排名




书目名称Cancer Drug Safety and Public Health Policy网络公开度




书目名称Cancer Drug Safety and Public Health Policy网络公开度学科排名




书目名称Cancer Drug Safety and Public Health Policy被引频次




书目名称Cancer Drug Safety and Public Health Policy被引频次学科排名




书目名称Cancer Drug Safety and Public Health Policy年度引用




书目名称Cancer Drug Safety and Public Health Policy年度引用学科排名




书目名称Cancer Drug Safety and Public Health Policy读者反馈




书目名称Cancer Drug Safety and Public Health Policy读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:47:44 | 显示全部楼层
Book 2022nalysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety
发表于 2025-3-22 03:17:24 | 显示全部楼层
发表于 2025-3-22 06:28:11 | 显示全部楼层
发表于 2025-3-22 09:18:55 | 显示全部楼层
发表于 2025-3-22 16:18:36 | 显示全部楼层
发表于 2025-3-22 17:17:44 | 显示全部楼层
https://doi.org/10.1007/978-3-540-87866-7 Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38(08):905–907. .). Prevailing opinion suggests that low reporting rates reflect time constraints.
发表于 2025-3-22 21:34:33 | 显示全部楼层
发表于 2025-3-23 04:00:48 | 显示全部楼层
发表于 2025-3-23 07:05:39 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-24 18:06
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表